Who Owns Cardinal Health Specialty Pharmacy?

Cardinal Health entered the specialty pharmacy market through a combination of internal development and acquisitions. The company's core pharmaceutical distribution business had long served retail pharmacies, hospitals, and health systems. Specialty pharmacy was a natural extension of this distribution capability, focused on a specific category of high-cost, complex medications.

Specialty drugs treat chronic, complex, or rare conditions. These medications often require special handling, such as cold chain storage, and may involve injectable or infusable administration. Patients taking specialty medications typically need additional support services, including prior authorization assistance, adherence monitoring, and side effect management. Standard retail pharmacies are generally not equipped to handle these requirements.

Cardinal Health built its specialty pharmacy capabilities over several years. The company leveraged its existing pharmaceutical distribution infrastructure to store, handle, and ship specialty medications. It developed clinical support programs to help patients manage complex treatment regimens.

A significant strategic move came through the development of The Specialty Alliance, Cardinal Health's multi-specialty management services organization (MSO) platform. MSOs provide administrative, contracting, and practice management services to physician practices. In the specialty pharmacy context, MSOs create referral channels. When a physician in an affiliated practice prescribes a specialty medication, the MSO infrastructure can route the prescription to Cardinal Health's specialty pharmacy for fulfillment.

In November 2025, The Specialty Alliance completed the acquisition of Solaris Health, the country's largest urology MSO with over 750 providers. This acquisition expanded Cardinal Health's referral network in urology, a specialty with growing pharmaceutical treatment options for prostate cancer, bladder cancer, and other conditions.

In the third quarter of fiscal year 2026, Cardinal Health announced that Specialty Networks and The Specialty Alliance entered an arrangement to partner with a pharmaceutical company on a multi-year study. The study focuses on understanding real-world outcomes for patients receiving care at community gastroenterology clinics. Specialty Networks will perform the analysis of the results. This partnership demonstrates how Cardinal Health is using its specialty pharmacy and MSO platforms to generate real-world evidence, which is increasingly valuable to pharmaceutical companies and regulators.

The Pharmaceutical and Specialty Solutions segment has been the primary growth engine for Cardinal Health. In the second quarter of fiscal year 2026, the segment's profit grew 29% to $687 million. In the third quarter, the segment continued to perform strongly. The company attributed this growth to brand and specialty product contributions, MSO platform acquisitions, and favorable generics program performance.

Cardinal Health's specialty pharmacy business also benefits from broader industry trends. The specialty drug share of total U.S. pharmacy spending has been increasing steadily. Specialty medications now account for over 50% of total pharmacy drug spend, despite representing a small fraction of total prescriptions. This shift is driven by the introduction of new biologics, gene therapies, and other high-cost treatments for conditions that were previously difficult to treat.